| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RPTX | Common Stock | Sale | -$576K | -16.9K | -0.52% | $34.12 | 3.26M | Aug 17, 2021 | See Footnotes | F1, F2, F5 |
| transaction | RPTX | Common Stock | Sale | -$17.5K | -512 | -0.52% | $34.12 | 98.7K | Aug 17, 2021 | See Footnotes | F3, F4, F5 |
| transaction | RPTX | Common Stock | Sale | -$96.9K | -2.85K | -0.09% | $33.99 | 3.26M | Aug 18, 2021 | See Footnotes | F2, F5, F6 |
| transaction | RPTX | Common Stock | Sale | -$2.65K | -78 | -0.08% | $33.99 | 98.6K | Aug 18, 2021 | See Footnotes | F4, F5, F7 |
| Id | Content |
|---|---|
| F1 | These shares of the Issuer's common stock were sold in a block order at price of $34.12 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP ("OPI VII"). |
| F2 | These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII. |
| F3 | These shares of the Issuer's common stock were sold in a block order at price of $34.12 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited ("OPM"). |
| F4 | These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM. |
| F5 | This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. |
| F6 | These shares of the Issuer's common stock were sold in a block order at price of $33.99 pursuant to a Rule 10b5-1 trading plan established by OPI VII. |
| F7 | These shares of the Issuer's common stock were sold in a block order at price of $33.99 pursuant to a Rule 10b5-1 trading plan established by OPM. |